1 / 6
Laboratory Research Material
Ovagen
20 mg per vial · Lyophilized powder
Laboratory Research Material
Ovagen 20 mg per vial
$54.99
- Compound
- Ovagen
- Amount per vial
- 20 mg
- Form
- Lyophilized powder
- Packaging
- 1 × 3 mL vial, boxed
- Shipping
- FedEx 2DayShips from the U.S. Estimated arrival2 business days after dispatchWeekday dispatch · 4 p.m. ET cutoff
Delivery details
Estimated for in-stock orders using FedEx 2Day. Weekends and FedEx closures are excluded. Holiday pickups, destination and carrier delays can affect arrival. Alaska and Hawaii may take longer.
In stock (can be backordered)
Free U.S. shipping on orders $199+
Important
Research Use Notice
All articles and product information provided on this website are for informational and educational purposes only. The products offered on this website are intended solely for research and laboratory use. These products are not intended for human or animal consumption. They are not medicines or drugs and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Do not administer these products to humans or animals.
Product Documentation
Details, specifications, and documents
Description
Ovagen 20 mg
Buy Ovagen 20 mg for laboratory research, supplied as lyophilized powder in one boxed 3 mL vial.
Ovagen is a short research peptide associated with the EDL reference sequence: glutamic acid-aspartic acid-leucine.
Match the peptide to the experiment
EDL contains three amino-acid residues. It is distinct from AED, which contains alanine, glutamic acid and aspartic acid, and from a tissue-derived mixture of peptides. A paper that compares those preparations is not describing three interchangeable versions of the same material.
The term bioregulator is used for this short-peptide research family. It does not, by itself, identify a receptor or establish an organ-specific effect. Match the sequence and supplied chemical form to the experiment rather than choosing a material solely by its catalog name.
What the EDL study measured
A 2015 kidney-tissue study compared EDL and AED with a polypeptide complex extracted from calf kidneys. The cultures came from young and old rats. The authors reported proliferation and apoptosis-related changes, with the short peptides producing smaller effects than the complex in that system.
That comparison provides a specific research context: defined short peptides and a peptide mixture tested in cultured kidney tissue. It does not establish liver repair, a whole-animal response or a human benefit for Ovagen. The study’s preparation also does not certify the identity or performance of a commercial lot.
Review the product and lot documentation
Open COA & Documents for the available reports and product files. Match the product and lot before interpreting a result, and check identity, chromatographic purity and measured content as separate questions.
The 20 mg label gives the amount per vial; it is not a solution concentration. Likewise, 3 mL describes the container capacity, not a prescribed preparation volume. Use handling, solvent and storage information applicable to the supplied material and your laboratory method. This presentation is a research powder, not a capsule or prepared solution.
Additional information
| CAS No. | 147732-56-7 |
|---|---|
| Purity | ≥99% |
| Synthesis Method | Solid-phase synthesis |
| Format | Lyophilized powder |
| Solubility | Water or validated laboratory buffer |
| Stability & Storage | Up to 24 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Applications | Ovarian function studies, hormonal balance research, reproductive health exploration |
| Appearance | White to off-white powder |
| Regulatory/Compliance | Not for human consumption. For research use only. |
| Safety Information | MSDS available upon request |
COA & Documents
Independent lot testing
Ovagen 20mg Certificate of Analysis
This product has featured batch-specific third-party laboratory documentation. The Pure Lab Peptides summary presents selected source-report fields in a consistent format; the linked original laboratory report controls if any information differs.
- Lot number
- 74421
- Report number
- COA261057-019
- Date tested
- August 11, 2026
- Reported purity
- 99.6%
- Labeled content
- 20 mg
Product documents
Product information and laboratory resources. For lot-specific results, use the COA above.
Product & packaging information
Labeled amount, physical form and packaging for Ovagen 20mg.
Revision 0.4 · 2026-10-05Download PDFLaboratory handling guide
General guidance for applicable lyophilized research materials. Not a product-specific SDS.
Revision 1.0 · 2026-09-22Download PDFGeneral guides & resources
Reading a COA & Verifying Your Lot
PDF · Revision 1.0Receiving, Storage & Traceability Record
PDF · Revision 1.0Research Use & Documentation Scope
PDF · Revision 1.0
Need Assistance?
Questions about product documentation?
Contact our support team for help with product records, lot information, orders or certificate verification.